ClinicalTrials.govpublic full text
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
herpes simplex, first time in human, healthy participants, recurrent genital herpes, herpes simplex virus, reactogenicity, safety, immune response, efficacy, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 850904
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.